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Abstract
Background: Deregulation of β-catenin is associated with malignant transformation; however, its relationship with 
potentially malignant and malignant oral processes is not fully understood. The aim of this study was to determine 
and compare the nuclear β-catenin expression in oral dysplasia and oral squamous cell carcinoma (OSCC).
Material and Methods: Cross sectional study. Immunodetection of β-catenin was performed on 72 samples, with 
the following distribution: 21 mild dysplasia, 12 moderate dysplasia, severe dysplasia 3, 36 OSCC including 19 
well differentiated, 15 moderately differentiated and 2 poorly differentiated. Through microscopic observation 
the number of positive cells per 1000 epithelial cells was counted. For the statistical analysis, the Kruskal Wallis 
test was used.
Results: Nuclear expression of β-catenin was observed in all samples with severe and moderate dysplasia, with a 
median of 267.5, in comparison to mild dysplasia whose median was 103.75. Only 10 samples (27.7%) with OSCC 
showed nuclear expression, with statistically significant differences between groups (p < 0.05).
Conclusions: Our results are consistent with most of the reports which show increased presence of β-catenin in 
severe and moderate dysplasia compared to mild dysplasia; however the expression of nuclear β-catenin decreased 
after starting the invasive neoplastic process. This suggests a role for this protein in the progression of dysplasia 
and early malignant transformation to OSCC. Immunodetection of β-catenin could be a possible immune marker 
in the detection of oral dysplasia.
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Introduction
Oral Squamous Cell Carcinoma (OSCC) is the most 
common malignancy of the oral cavity, and its early di-
agnosis is essential to improve patient survival and sig-
nificantly reduce mortality rates (1). Most OSCC may be 
preceded by visible clinical changes in the oral mucosa; 
the most common are leukoplakia and erythroplakia 
(2,3). Both lesions are provisional clinical diagnoses. 
Therefore, they require a histopathology study for their 
definitive diagnosis, which can correspond to epithe-
lial hyperplasia, hyperkeratosis, epithelial dysplasia or 
even carcinoma (4,5). Dysplasia diagnosis is usually 
quite complex and subjective; consequently some mark-
ers of cellular proliferation like Ki-67 have attempted 
to contribute to a more objective diagnosis (6,7). Some 
studies have shown that the percentage of Ki-67 posi-
tive cells increased according to the degree of severity 
(8-11). Therefore, this marker is a useful complement of 
the diagnosis of epithelial dysplasia. However, the mo-
lecular alterations and biological mechanisms leading 
to progression to OSCC are not fully understood and 
several molecular markers are under study.
The Wnt signaling pathway involves highly conserved 
genes for proteins whose biological functions are char-
acterized by the growth, proliferation and cellular dif-
ferentiation (12). Hitherto, we have recognized three 
different routes serving the Wnt pathway: the canoni-
cal pathway or Wnt-β-catenin pathway, the planar cell 
polarity and the Wnt-dependent Ca2+ (13). The Wnt-β-
catenin pathway is regulated by the intracellular levels 
of β-catenin protein (14,15), which despites being an ef-
fector molecule of the Wnt signal activation, it is also a 
protein involved in cell adhesion with E-cadherin. In the 
absence of Wnt signals, β-catenin is targeted for degra-
dation via the proteasome, by phosphorylation through 
a multiprotein complex composed of a serine/threonine 
kinase, glycogen synthase kinase 3b (GSK-3b) and a 
product of tumor suppressor gene: the adenomatous 
polyposis coli (APC) (15,16). Inhibition of β-catenin 
degradation caused by Wnt ligand results in the accu-
mulation of this cytoplasmic protein and subsequent 
translocation to the nucleus, forming a complex with 
Lymphoid Stimulating Factor-1/T cell Factor (LEF-1/
TCF) that displaces protein Groucho and assumes the 
function of co-activator, inducing transcription of tar-
get genes of Wnt signaling pathway, associated with cell 
growth and proliferation (17,18). Therefore, if this route 
presents changes its performance it can lead to uncon-
trolled cell growth and tumor formation.
The stabilization of β-catenin is an early event in car-
cinogenesis. Several reports have demonstrated aberrant 
activation of Wnt signaling pathway in various human 
tumors, including colorectal, gastric and melanoma. 
Given that, there is considerable evidence of abnor-
malities in the Wnt signaling pathway in tumorigenesis 
(19,20). Based on the evidence presented, and consid-
ering that currently there is no single marker or set of 
markers that reliably can be used to predict malignant 
transformation of oral dysplasia, the objective of this 
study is to determine and compare the nuclear β-catenin 
expression in oral dysplasia and OSCC. 
Material and Methods 
-1.1 Case selection
The study was approved by the Ethical Committee 
Board from the Faculty of Dentistry, University of 
Chile. Informed consent was obtained from all patients 
according to the Declaration of Helsinki.
The present study examined 72 formalin fixed paraf-
fin-embedded samples from the Pathological Anatomy 
Laboratory, Faculty of Dentistry, Universidad de Chile: 
36 of these samples had a clinical diagnosis of oral leu-
koplakia or erythroplakia and histopathological diagno-
sis of dysplasia and 36 had histopathological diagnosis 
of OSCC. Clinical records were reviewed to collect 
patient’s demographic data (gender, age) and clinical 
features of the lesions (clinical diagnosis, localization). 
Histological classification was assessed independently 
by two oral pathologists in sections previously stained 
with hematoxylin-eosin. Dysplasias were classified as: 
a) mild dysplasia (21 cases) 19 of which (90.47 %) were 
leukoplakias and 2 (9.5 %) were erythroplakias, b) mod-
erate dysplasia (12 cases), 10 of them (83.3 %) and 2 
(16.6 %) were leukoplakias and erythroplakias respec-
tively and severe dysplasia (3 cases). All of them had 
a clinical diagnosis of leukoplakia. Malignant samples 
were classified according to their degree of differentia-
tion, corresponding to 19 cases of well differentiated 
OSCC (52.78 %); 15 cases of moderately differentiated 
OSCC (41.66 %) and 2 cases of poorly differentiated 
OSCC (5.55 %). Three normal oral mucosa samples 
were included as controls.
-1.2 Immunohistochemistry
Four μm sections from paraffin blocks of each case 
were obtained and collected in positively charged slides 
(Lab Cellpath, England). Later they were dewaxed in 
xylene and rehydrated, descending alcohols to distilled 
water. Immunohistochemical staining was performed 
using the streptavidin-avidin-biotin complex (ABC) 
and the reaction was visualized with diaminobenzidine 
tetrahydrochloride (DAB). Sections were placed in so-
dium citrate buffer (pH 6) for 45 minutes in a pressure 
cooker for antigen retrieval, and then they were washed 
with PBS for 5 min; endogenous peroxidase activ-
ity was blocked by incubating the sections in H2O2 at 
3% in methanol at room temperature for 30 minutes. 
The sections were preincubated with horse serum for 
20 minutes at room temperature and then incubated for 
30 minutes with primary antibodies (β-catenin, Dako 
laboratory, USA and Ki- 67, Cell Marque Laboratory, 
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USA) 1:200 dilution, ready to use (RTU) respectively, 
in a moist chamber at 37°C. Sections were then washed 
with PBS for 5 min and incubated with biotinylated sec-
ondary antibody for 30 min at 37°C and then with per-
oxidase-conjugated streptavidin (Universal Detection 
System Vectastain Elite Kit wide spectrum ABC-HRP, 
RTU, Vector-USA, EE.UU) for 20 minutes at 37°C. The 
reaction was finally visualized with diaminobenzidine 
(DAB) and staining with Harris hematoxylin. Negative 
controls were obtained by substitution of the primary 
antibody with PBS.
-1.3 β-catenin and Ki-67 evaluation
The cellular localization of β-catenin was classified as 
membranous, cytoplasmic or nuclear, depending on the 
immunolocalization pattern. Intensity of membranous 
staining was assessed as mild, moderate or intense. 
In non-homogeneous cases, the predominant intensity 
(over 70% of cells) was recorded. Nuclear and cytoplas-
mic staining was recorded as positive or negative.
Quantification of nuclear β-catenin immunostaining 
was assessed by light microscopic examination with 
40x magnification. Five randomly selected fields with 
presence of dysplastic epithelium and/or neoplastic ac-
cordingly were assessed, which were photographed on 
Olympus BX41 microscope using the SE Premium Mi-
crometrics program. In these photomicrographs, 1000 
epithelial cells were counted per case with the Image J 
program, determining the number of positive cells.
Nuclear distribution of Ki-67 in the epithelium was used 
to corroborate the degree of dysplasia and architectural 
changes of the epithelium.
-1.3.1 Statistical Analysis
An exploratory data analysis was performed using 
descriptive statistics. Kruskal Wallis test was used. A 
value of significance of 5% or less (p < 0.05) to accept 
statistically significant differences was considered. All 
statistical tests were performed using Stata 11.0 soft-
ware.
Results
-2.1 Patients features
Table 1 summarizes the clinicopathological features of 
all cases examined in the present study. The average age 
for patients with dysplasia was 58 years (range 30 to 79 
years), compared with patients with OSCC which was 
65 years (range 45 to 91 years).
The most frequent location in mild dysplasia was in 
gums, both moderate and severe dysplasia was in 
tongue and OSCC cases were found mainly in tongue 
and cheek.
-2.2 Immunohistochemical evaluation of Ki-67
Immunostaining with Ki-67 in mild dysplasia was 
only present in the lower third of the epithelium. In 
moderate dysplasia, in the middle and lower third of the 
epithelium, as in severe dysplasia, which was observed 
in some cases also in the upper third of the epithelium, 
OSCC samples showed expression of Ki-67 throughout 
the epithelium. In samples of normal oral mucosa, 
scarce cell proliferation was observed in the basal layer 
of the epithelium (Figs. 1a,b, 2).
-2.3 Immunohistochemical evaluation of β-catenin
In all samples of normal oral mucosa epithelium, 
localization of β-catenin was detected in the cell 
membrane and there was negative immunostaining at 
cytoplasm and/or nuclear level. All samples of dysplasia 
and OSCC showed positive cytoplasmic immunostaining 
in all layers of the epithelium. Expression in the cell 
membrane in all samples was positive and their intensity 
decreased to less differentiated and usually lost in 
the upper layers of the epithelium. In mild dysplasia, 
MD
        N (%) 
MoD
N (%) 
SD 
N (%) 
WD OSCC 
N (%) 
MD OSCC 
N (%) 
PD OSCC 
N (%) 
Total cases 21 (100) 12 (100) 3 (100) 19 (100) 15 (100) 2 (100) 
Gender 
         Female 
         Male 
13 (62) 
8 (38) 
9 (75) 
3 (25) 
2 (67) 
1 (33) 
10 (53) 
9 (47) 
7 (47) 
8 (53) 
2 (100) 
0 (0) 
Average age 60 68 55 66 65 53 
Location       
        Tongue 
        Palate 
        Floor of mouth 
        Gums 
        Mandible 
        Cheek 
       No records 
5 (24) 
2 (9.5) 
0 (0) 
10 (47) 
1 (5) 
1 (5) 
2 (9.5) 
6 (50) 
1 (8.3) 
1 (8.3) 
3 (25) 
1 (8.3) 
0 (0) 
0 (0) 
2 (67) 
0 (0) 
1 (33) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
8 (42) 
2 (10.5) 
0 (0) 
1 (5.3) 
2 (10.5) 
4 (21.2) 
2 (10.5) 
4 (27) 
0 (0) 
2 (13) 
0 (0) 
1 (7) 
5 (33) 
3  (20) 
1 (50) 
0 (0) 
1 (50) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
Table 1.  Clinicopathological features of all cases in this study.
MD: mild dysplasia; MoD: moderate dysplasia, SD: severe dysplasia, WD OSCC: well differentiated oral squamous cell carcinoma, 
MD OSCC: moderate differentiated oral squamous cell carcinoma, PD OSCC: poorly differentiated oral squamous cell carcinoma.
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15 of 21 samples (71.42%) showed nuclear labeling, 
whereas 100% of the samples with moderate dysplasia 
(12 samples) and severe dysplasia (3 samples) showed 
nuclear labeling of β-catenin. Only 10 OSCC samples 
(27.7%) showed nuclear expression, 6 of them were well 
differentiated and 4 moderately differentiated (Table 
2). The nuclear expression in moderate and severe 
dysplasia were mainly located in the lower third of the 
epithelium, compared to samples from OSCC where in 
most samples they were located in upper stratas (Figs. 
3a,b, 4).
Quantification of nuclear expression of β-catenin in 
mild dysplasia, moderate dysplasia in conjunction with 
severe dysplasia and OSCC showed a median of 103.75, 
267.5 and 0 respectively. Differences in the nuclear 
expression of β-catenin between dysplasia and OSCC 
were observed (p<0.05) (Table 3).
Discussion
Our objective was to determine and compare the nucle-
ar expression of β-catenin in oral dysplasia and OSCC. 
Some studies have been undertaken to try to determine 
whether the expression of Ki-67 antigen is related to the 
presence of epithelial dysplasia (21), since the increase 
in cell proliferation is considered to be feature for ma-
lignant progression (22,23). The proliferation marker 
Ki-67 is expressed in all phases of the cell cycle except 
G0 (24). Several studies have demonstrated that this 
protein is a reliable marker of cell proliferation on both 
malignant and potentially malignant lesions. Zoeller et 
al., (9) studying epithelial dysplasia observed that the 
percentage of cells expressing Ki-67 increases accord-
ing to the histopathologic malignancy degree. Saito et 
al., (25) found that expression of Ki-67 increased ac-
cording to cell proliferation. Moreover, Mimica et al., 
(26) and Cambruzzi et al., (27) showed an increase 
in Ki-67 to low degree of epithelial differentiation in 
OSCC. Therefore, as these authors suggest, Ki-67 is 
a good marker of cell proliferation and it also makes 
it possible to establish the dysplasia degree with more 
certainty. Given that, this marker was used in this study 
to confirm the degree of epithelial dysplasia on samples 
Fig. 1. Samples of normal oral mucosa (A), mild dysplasia 
(C) with hematoxylin-eosin staining.
Immunohistochemical localization of Ki-67 at the basal 
strata of the epithelium in normal oral mucosa (B), in mild 
dysplasia the protein locates mainly in the lower third of the 
epithelium (D).
Samples of moderate (E) and severe dysplasia (G) with 
hematoxylin-eosin staining.
Immunohistochemical localization of Ki-67 in moderate 
dysplasia (F) the nuclear expression of Ki-67 is located at 
the medium and lower third of the epithelium; severe dys-
plasia (H) immunohistochemical localization of Ki-67 at 
the lower, medium and higher thirds of the epithelium.
Fig. 2. Samples of well differentiated OSCC (I), moderate 
differentiated OSCC (K) and poorly differentiated OSCC 
(M) with hematoxylin-eosin staining.
Immunolocalization of Ki-67 in well differentiated OSCC 
(J); moderate differentiated OSCC (L) and poorly differ-
entiated OSCC (N) is observed in all epithelia strata.
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previously diagnosed with hematoxylin-eosin staining, 
confirming that cell proliferation increased with greater 
severity of injuries, corroborating the diagnosis and the 
severity of each of the dysplasias included in our study.
The critical role in Wnt/β-catenin signaling pathway in 
the development of many human tumors prompted us 
to investigate if nuclear expression of β-catenin in dys-
plasia and OSCC exists, since this molecule is not only 
Groups 
Total
cases 
Intensity of membranous 
staining 
Cytoplasmic staining Nuclear staining 
  Mild Moderate Intense Positive Negative Positive Negative 
NOM 3 0 0 3 0 3 0 3 
MD 21 2 5 14 21 0 15 6 
MoD 12 5 4 3 12 0 12 0 
SD 3 2 0 1 3 0 3 0 
WD OSCC 19 11 5 3 19 0 6 13 
MD OSCC 15 10 3 2 15 0 4 11 
PD OSCC 2 2 0 0 2 0 0 2 
Table 2. Localization of β-catenin in the study groups.
NOM: normal oral mucosa MD: mild dysplasia; MoD: moderate dysplasia, SD: severe dysplasia, WD OSCC: well dif-
ferentiated oral squamous cell carcinoma, MD OSCC: moderate differentiated oral squamous cell carcinoma, PD OSCC: 
poorly differentiated oral squamous cell carcinoma.
Fig. 3. Immunohistochemical localization of β-catenin in 
normal oral mucosa (A-B), in which only membrane ex-
pression is observed; mild dysplasia (C-D), where the pro-
tein is mainly localized at membrane and cytoplasm and 
the nuclear expression is present but at the lowest degree 
(D). Immunohistochemical localization of β-catenin in 
moderate dysplasia (E-F), where the nuclear expression 
of β-catenin is greater; severe dysplasia (G-H) where the 
protein strongly expressed at the lower layers of the epi-
thelium.
Fig. 4. Immunohistochemical localization of β-catenin in 
well diferentiated OSCC (I-J), the protein is primarily lo-
calized at membranous and cytoplasmic level, the nuclear 
expression is very low: moderately differentiated OSCC 
(K-L), the membrane protein expression is lost to a lesser 
degree of differentiation, as in the poorly differentiated 
OSCC samples where no nuclear expression of β-catenin 
observed (M-N).
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an essential integral part in cell adhesion  (28),  but it 
also plays an important role in cell proliferation induc-
tion. Cytoplasmic accumulation and subsequent nuclear 
translocation of β-catenin may be the result of canonical 
Wnt signaling pathway activation or to pathway impair-
ment due to mutations in some of its components and 
therefore its cytoplasmic overexpression as its nuclear 
localization is known to be associated with malignant 
transformation in different types of cancers (29-31). 
However, its expression in oral dysplasia and OSCC 
has been poorly investigated. A considerable number 
of β-catenin studies in this type of oral lesions focuses 
on its expression as a component of the cell adhesion 
system, therefore to their membrane detection, since 
it has been found a relationship between β-catenin ex-
pression and cell differentiation degree (32), where the 
decrease in membrane expression of this protein has 
been associated with loss of cell differentiation (33). 
This is evidenced by the reduced membrane expression 
of this protein (32). Williams et al., (34) showed that 
membranous expression of β-catenin was reduced both 
in severe dysplasia and carcinoma in situ. Bankfalvi et 
al., (35,36) indicate that investigated areas of dysplastic 
mucosa adjacent to tumor are associated with a limited 
loss of β-catenin. Laxmidevi et al., (33) describe that 
membranous localization of β-catenin was correlated 
with the degree of differentiation in OSCC, showing a 
decrease of it to less differentiated OSCC, just as the 
results obtained by Yu et al., (37) Gasparoni et al., (38) 
and Bagutti et al., (39). Therefore, the reduced mem-
brane expression and increased cytoplasmic expression 
of β-catenin reflect the aggressive nature of OSCC. Our 
results agree that a lesser differentiation degree in OSCC 
is associated with a progressive reduction of membra-
nous expression of β-catenin. However, there are few 
studies that indicate the expression of β-catenin in hu-
man oral dysplasia and most of them focus on OSCC.
As for β-catenin nuclear expression some authors point 
out that there is an intracytoplasmic and nuclear ac-
cumulation of β-catenin in 62.5% of dysplastic lesions 
induced in oral mucosa of rats (40). Ishida et al., (41) 
indicates that β-catenin nuclear expression increased 
during the severity progression of dysplastic oral leu-
koplakia, also observing nuclear expression in 10 out 
of 15 samples from OSCC and reduced membrane ex-
pression of the protein which they associated with the 
appearance of cell invasion or metastasis. Our results 
show an increase nuclear expression of β-catenin to a 
greater severity of oral dysplasia, but not in OSCC, in 
where nuclear expression was much lower compared 
to the aforementioned study, in which they only indi-
cate the presence of the protein and not the amount of it 
present in a lesion, or the location of the protein in the 
epithelial layer. This is relevant because it indicates that 
β-catenin nuclear expression on basal cells of the lower 
strata of the epithelium will show that this protein might 
function as a transcription factor for proliferative acti-
vation of these cells, which agrees on our results, where 
the nuclear localization of β-catenin was mainly found 
on lower and middle epithelial layers as the severity of 
dysplasia was greater.
Our results are in line with those reported in previous 
studies in which increased presence of β-catenin is 
shown in moderate and severe dysplasia compared to 
oral mucosa mild dysplasia. The results of this study 
suggest that nuclear expression of this protein in epithe-
lia lower strata may be related to cell proliferation, and 
more importantly that most of the nuclear expression 
of β-catenin in moderate and severe dysplastic lesions 
would be involved in the malignant transformation to-
wards the development of OSCC, which is why it is sug-
gested that β-catenin is a potential marker for dysplastic 
lesions of the oral cavity.
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